Archives of Pharmacal Research

, Volume 39, Issue 11, pp 1537–1547 | Cite as

Targeting IL-17 in autoimmunity and inflammation

Review

Abstract

The discovery of two distinct subsets of helper T cells, IFN-γ-producing Th1 cells and IL-4-producing Th2 cells, about three decades ago enabled us to understand the immunopathology of cell-mediated and allergic inflammatory diseases in humans. The observation that T cell-mediated experimental autoimmune diseases can be induced in mice lacking Th1 and Th2 cell responses prompted many immunologists to hypothesize that there might be additional subsets in helper T cell population which mediate autoimmunity in the absence of Th1 and Th2 cells. Consequently, multiple independent research groups identified IL-17-expressing RORγt+CD4+ T cell population as a distinct subset of helper T cells which promotes autoimmune tissue inflammation. Subsequent studies have revealed that innate immune cells, including γδ T cells, NKT cells and innate lymphoid cells, also produce type 17 cytokines and contribute to tissue inflammation. In this review, we discuss our current understanding on the biology of IL-17 and the therapeutic potential of targeting IL-17 for the treatment of immune disorders in humans.

Keywords

IL-17 Th17 cell Autoimmunity Anti-IL-17 RORγt 

Notes

Acknowledgments

We appreciate Inbo Shim and Da-Sol Kuen for editing manuscript. This work is supported by Grants 2014R1A2A1A11054364 (YC) and 0430-20150023 (Basic Science Research Program) (YJP) from the National Research Foundation of Korea (NRF) Grant funded by the Korean government (MEST).

Compliance with ethical standards

Conflict of Interest

The authors declare no competing financial interest.

References

  1. Alunno A, Carubbi F, Cafaro G, Pucci G, Battista F, Bartoloni E, Giacomelli R, Schillaci G, Gerli R (2015) Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis. Expert Opin Biol Ther 15:1727–1737CrossRefPubMedGoogle Scholar
  2. Auriemma M, Vianale G, Amerio P, Reale M (2013) Cytokines and T cells in atopic dermatitis. Eur Cytokine Netw 24:37–44PubMedGoogle Scholar
  3. Bartlett HS, Million RP (2015) Targeting the IL-17-T(H)17 pathway. Nat Rev Drug Discov 14:11–12CrossRefPubMedGoogle Scholar
  4. Beringer A, Noack M, Miossec P (2016) IL-17 in chronic inflammation: from discovery to targeting. Trends Mol Med 22:230–241CrossRefPubMedGoogle Scholar
  5. Bullens DM, Truyen E, Coteur L, Dilissen E, Hellings PW, Dupont LJ, Ceuppens JL (2006) IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx? Respir Res 7:135CrossRefPubMedPubMedCentralGoogle Scholar
  6. Campa M, Mansouri B, Warren R, Menter A (2016) A review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis. Dermatol Ther 6:1–12CrossRefGoogle Scholar
  7. Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L, Miossec P (1999) Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 42:963–970CrossRefPubMedGoogle Scholar
  8. Chabaud M, Page G, Miossec P (2001) Enhancing effect of IL-1, IL-17, and TNF-alpha on macrophage inflammatory protein-3alpha production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines. J Immunol 167:6015–6020CrossRefPubMedGoogle Scholar
  9. Chae WJ, Gibson TF, Zelterman D, Hao L, Henegariu O, Bothwell AL (2010) Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis. Proc Natl Acad Sci USA 107:5540–5544CrossRefPubMedPubMedCentralGoogle Scholar
  10. Chan AC, Carter PJ (2010) Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 10:301–316CrossRefPubMedGoogle Scholar
  11. Chang SH, Dong C (2007) A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res 17:435–440PubMedGoogle Scholar
  12. Chang SH, Park H, Dong C (2006) Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor. J Biol Chem 281:35603–35607CrossRefPubMedGoogle Scholar
  13. Chang SH, Reynolds JM, Pappu BP, Chen G, Martinez GJ, Dong C (2011) Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E. Immunity 35:611–621CrossRefPubMedGoogle Scholar
  14. Chang SH, Mirabolfathinejad SG, Katta H, Cumpian AM, Gong L, Caetano MS, Moghaddam SJ, Dong C (2014) T helper 17 cells play a critical pathogenic role in lung cancer. Proc Natl Acad Sci USA 111:5664–5669CrossRefPubMedPubMedCentralGoogle Scholar
  15. Corneth OB, Mus AM, Asmawidjaja PS, Klein Wolterink RG, van Nimwegen M, Brem MD, Hofman Y, Hendriks RW, Lubberts E (2014) Absence of interleukin-17 receptor a signaling prevents autoimmune inflammation of the joint and leads to a Th2-like phenotype in collagen-induced arthritis. Arthritis Rheumatol 66:340–349CrossRefPubMedGoogle Scholar
  16. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L, To W, Kwan S, Churakova T, Zurawski S, Wiekowski M, Lira SA, Gorman D, Kastelein RA, Sedgwick JD (2003) Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421:744–748CrossRefPubMedGoogle Scholar
  17. Di Cesare A, Di Meglio P, Nestle FO (2008) A role for Th17 cells in the immunopathogenesis of atopic dermatitis? J Invest Dermatol 128:2569–2571CrossRefPubMedGoogle Scholar
  18. Dubinsky MC, Wang D, Picornell Y, Wrobel I, Katzir L, Quiros A, Dutridge D, Wahbeh G, Silber G, Bahar R, Mengesha E, Targan SR, Taylor KD, Rotter JI (2007) Western regional research alliance for pediatric IBD, IL-23 receptor (IL-23R) gene protects against pediatric crohn’s disease. Inflamm Bowel Dis 13:511–515CrossRefPubMedPubMedCentralGoogle Scholar
  19. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barmada MM, Rotter JI, Nicolae DL, Cho JH (2006) A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314:1461–1463CrossRefPubMedPubMedCentralGoogle Scholar
  20. Dyring-Andersen B, Skov L, Zachariae C (2015) Targeting IL-17 with ixekizumab in patients with psoriasis. Immunotherapy 7:957–966CrossRefPubMedGoogle Scholar
  21. Farahnik B, Beroukhim K, Abrouk M, Nakamura M, Zhu TH, Singh R, Lee K, Bhutani T, Koo J (2016) Brodalumab for the treatment of psoriasis: a review of phase III trials. Dermatol Ther (Heidelb) 6(2):111–124CrossRefGoogle Scholar
  22. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, Pin JJ, Garrone P, Garcia E, Saeland S, Blanchard D, Gaillard C, Das Mahapatra B, Rouvier E, Golstein P, Banchereau J, Lebecque S (1996) T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 183:2593–2603CrossRefPubMedGoogle Scholar
  23. Gaffen SL, Jain R, Garg AV, Cua DJ (2014) The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol 14:585–600CrossRefPubMedPubMedCentralGoogle Scholar
  24. Gladman DD, Farewell VT, Pellett F, Schentag C, Rahman P (2003) HLA is a candidate region for psoriatic arthritis. evidence for excessive HLA sharing in sibling pairs. Hum Immunol 64:887–889CrossRefPubMedGoogle Scholar
  25. Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, Zaba LC, Cardinale I, Nograles KE, Khatcherian A, Novitskaya I, Carucci JA, Bergman R, Krueger JG (2008) Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J Immunol 181:7420–7427CrossRefPubMedPubMedCentralGoogle Scholar
  26. Haak S, Croxford AL, Kreymborg K, Heppner FL, Pouly S, Becher B, Waisman A (2009) IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice. J Clin Invest 119:61–69PubMedGoogle Scholar
  27. Harper EG, Guo C, Rizzo H, Lillis JV, Kurtz SE, Skorcheva I, Purdy D, Fitch E, Iordanov M, Blauvelt A (2009) Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol 129:2175–2183CrossRefPubMedPubMedCentralGoogle Scholar
  28. Hayashida S, Uchi H, Moroi Y, Furue M (2011) Decrease in circulating Th17 cells correlates with increased levels of CCL17, IgE and eosinophils in atopic dermatitis. J Dermatol Sci 61:180–186CrossRefPubMedGoogle Scholar
  29. Hue S, Ahern P, Buonocore S, Kullberg MC, Cua DJ, McKenzie BS, Powrie F, Maloy KJ (2006) Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med 203:2473–2483CrossRefPubMedPubMedCentralGoogle Scholar
  30. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH, Psoriasis Study G, Durez P, Tak PP, Gomez-Reino JJ, Rheumatoid Arthritis Study G, Foster CS, Kim RY, Samson CM, Falk NS, Chu DS, Callanan D, Nguyen QD, Uveitis Study G, Rose K, Haider A, Di Padova F (2010) Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2:52ra72CrossRefPubMedGoogle Scholar
  31. Huh JR, Leung MW, Huang P, Ryan DA, Krout MR, Malapaka RR, Chow J, Manel N, Ciofani M, Kim SV, Cuesta A, Santori FR, Lafaille JJ, Xu HE, Gin DY, Rastinejad F, Littman DR (2011) Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing ROR gammat activity. Nature 472:486–490CrossRefPubMedPubMedCentralGoogle Scholar
  32. Isono F, Fujita-Sato S, Ito S (2014) Inhibiting ROR gammat/Th17 axis for autoimmune disorders. Drug Discov Today 19:1205–1211CrossRefPubMedGoogle Scholar
  33. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR (2006) The orphan nuclear receptor ROR gammat directs the differentiation program of proinflammatory IL-17 + T helper cells. Cell 126:1121–1133CrossRefPubMedGoogle Scholar
  34. Iwakura Y, Ishigame H, Saijo S, Nakae S (2011) Functional specialization of interleukin-17 family members. Immunity 34:149–162CrossRefPubMedGoogle Scholar
  35. Izcue A, Hue S, Buonocore S, Arancibia-Carcamo CV, Ahern PP, Iwakura Y, Maloy KJ, Powrie F (2008) Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity 28:559–570CrossRefPubMedPubMedCentralGoogle Scholar
  36. Jandus C, Bioley G, Rivals JP, Dudler J, Speiser D, Romero P (2008) Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum 58:2307–2317CrossRefPubMedGoogle Scholar
  37. Johansen C, Usher PA, Kjellerup RB, Lundsgaard D, Iversen L, Kragballe K (2009) Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol 160:319–324CrossRefPubMedGoogle Scholar
  38. Kobayashi T, Okamoto S, Hisamatsu T, Kamada N, Chinen H, Saito R, Kitazume MT, Nakazawa A, Sugita A, Koganei K, Isobe K, Hibi T (2008) IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease. Gut 57:1682–1689CrossRefPubMedGoogle Scholar
  39. Koenders MI, van den Berg WB (2015) Novel therapeutic targets in rheumatoid arthritis. Trends Pharmacol Sci 36:189–195CrossRefPubMedGoogle Scholar
  40. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, Martin TJ, Suda T (1999) IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103:1345–1352CrossRefPubMedPubMedCentralGoogle Scholar
  41. Kreymborg K, Etzensperger R, Dumoutier L, Haak S, Rebollo A, Buch T, Heppner FL, Renauld JC, Becher B (2007) IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis. J Immunol 179:8098–8104CrossRefPubMedGoogle Scholar
  42. Kryczek I, Wei S, Szeliga W, Vatan L, Zou W (2009) Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 114:357–359CrossRefPubMedPubMedCentralGoogle Scholar
  43. Lee JS, Tato CM, Joyce-Shaikh B, Gulen MF, Cayatte C, Chen Y, Blumenschein WM, Judo M, Ayanoglu G, McClanahan TK, Li X, Cua DJ (2015) Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability. Immunity 43:727–738CrossRefPubMedGoogle Scholar
  44. Li X, Kim KW, Cho ML, Ju JH, Kang CM, Oh HJ, Min JK, Lee SH, Park SH, Kim HY (2010) IL-23 induces receptor activator of NF-kappaB ligand expression in fibroblast-like synoviocytes via STAT3 and NF-kappaB signal pathways. Immunol Lett 127:100–107CrossRefPubMedGoogle Scholar
  45. Lim H, Kim YU, Sun H, Lee JH, Reynolds JM, Hanabuchi S, Wu H, Teng BB, Chung Y (2014) Proatherogenic conditions promote autoimmune T helper 17 cell responses in vivo. Immunity 40:153–165CrossRefPubMedPubMedCentralGoogle Scholar
  46. Linden A (2007) A role for the cytoplasmic adaptor protein Act1 in mediating IL-17 signaling. Sci STKE 2007(398):4CrossRefGoogle Scholar
  47. Liu C, Qian W, Qian Y, Giltiay NV, Lu Y, Swaidani S, Misra S, Deng L, Chen ZJ, Li X (2009) Act1, a U-box E3 ubiquitin ligase for IL-17 signaling. Sci Signal 2:ra63PubMedPubMedCentralGoogle Scholar
  48. Lowes MA, Russell CB, Martin DA, Towne JE, Krueger JG (2013) The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol 34:174–181CrossRefPubMedPubMedCentralGoogle Scholar
  49. Lubberts E (2015) The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol 11:562CrossRefPubMedGoogle Scholar
  50. Malik S, Want MY, Awasthi A (2016) The emerging roles of gamma-delta T cells in tissue inflammation in experimental autoimmune encephalomyelitis. Front Immunol 7:14CrossRefPubMedPubMedCentralGoogle Scholar
  51. Martin-Orozco N, Dong C (2009) The IL-17/IL-23 axis of inflammation in cancer: friend or foe? Curr Opin Investig Drugs 10:543–549PubMedGoogle Scholar
  52. Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, Hwu P, Restifo NP, Overwijk WW, Dong C (2009) T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31:787–798CrossRefPubMedPubMedCentralGoogle Scholar
  53. McAllister F, Henry A, Kreindler JL, Dubin PJ, Ulrich L, Steele C, Finder JD, Pilewski JM, Carreno BM, Goldman SJ, Pirhonen J, Kolls JK (2005) Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis. J Immunol 175:404–412CrossRefPubMedPubMedCentralGoogle Scholar
  54. Mei Y, Pan F, Gao J, Ge R, Duan Z, Zeng Z, Liao F, Xia G, Wang S, Xu S, Xu J, Zhang L, Ye D (2011) Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin Rheumatol 30:269–273CrossRefPubMedGoogle Scholar
  55. Menon B, Gullick NJ, Walter GJ, Rajasekhar M, Garrood T, Evans HG, Taams LS, Kirkham BW (2014) Interleukin-17+ CD8 +T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheumatol 66:1272–1281CrossRefPubMedPubMedCentralGoogle Scholar
  56. Metawi SA, Abbas D, Kamal MM, Ibrahim MK (2011) Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA. Clin Rheumatol 30:1201–1207CrossRefPubMedGoogle Scholar
  57. Miossec P, Korn T, Kuchroo VK (2009) Interleukin-17 and type 17 helper T cells. N Engl J Med 361:888–898CrossRefPubMedGoogle Scholar
  58. Molet S, Hamid Q, Davoine F, Nutku E, Taha R, Page N, Olivenstein R, Elias J, Chakir J (2001) IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol 108:430–438CrossRefPubMedGoogle Scholar
  59. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K, Gattinoni L, Wrzesinski C, Hinrichs CS, Kerstann KW, Feigenbaum L, Chan CC, Restifo NP (2008) Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112:362–373CrossRefPubMedPubMedCentralGoogle Scholar
  60. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, Sedgwick JD, Cua DJ (2003) Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 198:1951–1957CrossRefPubMedPubMedCentralGoogle Scholar
  61. Nakae S, Nambu A, Sudo K, Iwakura Y (2003) Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 171:6173–6177CrossRefPubMedGoogle Scholar
  62. Narbutt J, Wojtczak M, Zalinska A, Salinski A, Przybylowska-Sygut K, Kuna P, Majak P, Sysa-Jedrzejowska A, Lesiak A (2015) The A/A genotype of an interleukin-17A polymorphism predisposes to increased severity of atopic dermatitis and coexistence with asthma. Clin Exp Dermatol 40:11–16CrossRefPubMedGoogle Scholar
  63. Novatchkova M, Leibbrandt A, Werzowa J, Neubuser A, Eisenhaber F (2003) The STIR-domain superfamily in signal transduction, development and immunity. Trends Biochem Sci 28:226–229CrossRefPubMedGoogle Scholar
  64. O’Connor W Jr, Kamanaka M, Booth CJ, Town T, Nakae S, Iwakura Y, Kolls JK, Flavell RA (2009) A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol 10:603–609CrossRefPubMedPubMedCentralGoogle Scholar
  65. O’Quinn DB, Palmer MT, Lee YK, Weaver CT (2008) Emergence of the Th17 pathway and its role in host defense. Adv Immunol 99:115–163CrossRefPubMedGoogle Scholar
  66. Pappu R, Rutz S, Ouyang W (2012) Regulation of epithelial immunity by IL-17 family cytokines. Trends Immunol 33:343–349CrossRefPubMedGoogle Scholar
  67. Powrie F, Carlino J, Leach MW, Mauze S, Coffman RL (1996) A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells. J Exp Med 183:2669–2674CrossRefPubMedGoogle Scholar
  68. Punt S, Langenhoff JM, Putter H, Fleuren GJ, Gorter A, Jordanova ES (2015) The correlations between IL-17 vs. Th17 cells and cancer patient survival: a systematic review. Oncoimmunology 4:e984547CrossRefPubMedPubMedCentralGoogle Scholar
  69. Qian Y, Liu C, Hartupee J, Altuntas CZ, Gulen MF, Jane-Wit D, Xiao J, Lu Y, Giltiay N, Liu J, Kordula T, Zhang QW, Vallance B, Swaidani S, Aronica M, Tuohy VK, Hamilton T, Li X (2007) The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nat Immunol 8:247–256CrossRefPubMedGoogle Scholar
  70. Raychaudhuri SP (2013) Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol 44:183–193CrossRefPubMedGoogle Scholar
  71. Reynolds JM, Angkasekwinai P, Dong C (2010) IL-17 family member cytokines: regulation and function in innate immunity. Cytokine Growth Factor Rev 21:413–423CrossRefPubMedPubMedCentralGoogle Scholar
  72. Reynolds JM, Lee YH, Shi Y, Wang X, Angkasekwinai P, Nallaparaju KC, Flaherty S, Chang SH, Watarai H, Dong C (2015) Interleukin-17B antagonizes interleukin-25-mediated mucosal inflammation. Immunity 42:692–703CrossRefPubMedGoogle Scholar
  73. Rickel EA, Siegel LA, Yoon BR, Rottman JB, Kugler DG, Swart DA, Anders PM, Tocker JE, Comeau MR, Budelsky AL (2008) Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities. J Immunol 181:4299–4310CrossRefPubMedGoogle Scholar
  74. Rizzo HL, Kagami S, Phillips KG, Kurtz SE, Jacques SL, Blauvelt A (2011) IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J Immunol 186:1495–1502CrossRefPubMedGoogle Scholar
  75. Rothstein B, Gottlieb A (2016) Secukinumab for treating plaque psoriasis. Expert Opin Biol Ther 16:119–128CrossRefPubMedGoogle Scholar
  76. Rouvier E, Luciani MF, Mattei MG, Denizot F, Golstein P (1993) CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol 150:5445–5456PubMedGoogle Scholar
  77. Ruddy MJ, Wong GC, Liu XK, Yamamoto H, Kasayama S, Kirkwood KL, Gaffen SL (2004) Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members. J Biol Chem 279:2559–2567CrossRefPubMedGoogle Scholar
  78. Shahrara S, Pickens SR, Mandelin AM 2nd, Karpus WJ, Huang Q, Kolls JK, Pope RM (2010) IL-17-mediated monocyte migration occurs partially through CC chemokine ligand 2/monocyte chemoattractant protein-1 induction. J Immunol 184:4479–4487CrossRefPubMedPubMedCentralGoogle Scholar
  79. Shen F, Li N, Gade P, Kalvakolanu DV, Weibley T, Doble B, Woodgett JR, Wood TD, Gaffen SL (2009) IL-17 receptor signaling inhibits C/EBPbeta by sequential phosphorylation of the regulatory 2 domain. Sci Signal 2:ra8CrossRefPubMedPubMedCentralGoogle Scholar
  80. Silacci M, Lembke W, Woods R, Attinger-Toller I, Baenziger-Tobler N, Batey S, Santimaria R, von der Bey U, Koenig-Friedrich S, Zha W, Schlereth B, Locher M, Bertschinger J, Grabulovski D (2016) Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases. MAbs 8:141–149CrossRefPubMedGoogle Scholar
  81. Tong Z, Yang XO, Yan H, Liu W, Niu X, Shi Y, Fang W, Xiong B, Wan Y, Dong C (2012) A protective role by interleukin-17F in colon tumorigenesis. PLoS One 7:e34959CrossRefPubMedPubMedCentralGoogle Scholar
  82. Torres T, Romanelli M, Chiricozzi A (2016) A revolutionary therapeutic approach for psoriasis: bispecific biological agents. Expert Opin Investig Drugs 25(7):1–4CrossRefGoogle Scholar
  83. Wang R, Hasnain SZ, Tong H, Das I, Che-Hao Chen A, Oancea I, Proctor M, Florin TH, Eri RD, McGuckin MA (2015) Neutralizing IL-23 is superior to blocking IL-17 in suppressing intestinal inflammation in a spontaneous murine colitis model. Inflamm Bowel Dis 21:973–984CrossRefPubMedGoogle Scholar
  84. Wilke CM, Kryczek I, Wei S, Zhao E, Wu K, Wang G, Zou W (2011) Th17 cells in cancer: help or hindrance? Carcinogenesis 32:643–649CrossRefPubMedPubMedCentralGoogle Scholar
  85. Willenborg DO, Fordham S, Bernard CC, Cowden WB, Ramshaw IA (1996) IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J Immunol 157:3223–3227PubMedGoogle Scholar
  86. Woodrick RS, Ruderman EM (2011) Safety of biologic therapy in rheumatoid arthritis. Nat Rev Rheumatol 7:639–652CrossRefPubMedGoogle Scholar
  87. Wright JF, Guo Y, Quazi A, Luxenberg DP, Bennett F, Ross JF, Qiu Y, Whitters MJ, Tomkinson KN, Dunussi-Joannopoulos K, Carreno BM, Collins M, Wolfman NM (2007) Identification of an interleukin 17F/17A heterodimer in activated human CD4+ T cells. J Biol Chem 282:13447–13455CrossRefPubMedGoogle Scholar
  88. Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, Huso DL, Brancati FL, Wick E, McAllister F, Housseau F, Pardoll DM, Sears CL (2009) A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 15:1016–1022CrossRefPubMedPubMedCentralGoogle Scholar
  89. Xu T, Wang X, Zhong B, Nurieva RI, Ding S, Dong C (2011) Ursolic acid suppresses interleukin-17 (IL-17) production by selectively antagonizing the function of ROR gamma t protein. J Biol Chem 286:22707–22710CrossRefPubMedPubMedCentralGoogle Scholar
  90. Yang XO, Chang SH, Park H, Nurieva R, Shah B, Acero L, Wang YH, Schluns KS, Broaddus RR, Zhu Z, Dong C (2008) Regulation of inflammatory responses by IL-17F. J Exp Med 205:1063–1075CrossRefPubMedPubMedCentralGoogle Scholar
  91. Yao Z, Fanslow WC, Seldin MF, Rousseau AM, Painter SL, Comeau MR, Cohen JI, Spriggs MK (1995) Herpesvirus saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 3:811–821CrossRefPubMedGoogle Scholar

Copyright information

© The Pharmaceutical Society of Korea 2016

Authors and Affiliations

  • Byung-Seok Kim
    • 1
    • 2
  • Young-Jun Park
    • 1
  • Yeonseok Chung
    • 1
    • 2
  1. 1.Laboratory of Immune Regulation, Research Institute of Pharmaceutical SciencesSeoul National UniversitySeoulRepublic of Korea
  2. 2.BK21 Plus Program, College of PharmacySeoul National UniversitySeoulRepublic of Korea

Personalised recommendations